Vilon: A Literature Course on What the Published Studies Report

Vilon is the research designation for a synthetic short peptide, commonly described in the peptide literature as the dipeptide lysyl-glutamate (Lys-Glu). It appears in the published record almost entirely within a body of Russian gerontology and experimental-biology research, where it has been characterised as a “thymomimetic” peptide and studied in animals, cell cultures, and a small number of clinical reports in patients with diabetes mellitus (PMID 17152731).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, medication, or health decision. Nothing here is an instruction, a protocol, or a suggestion that any person use any compound.

How this course is organised

The course has six modules and a closing section. Each module summarises what the indexed literature contains, names the model and endpoints where the record describes them, and ends with a short statement of the limits of that evidence. Doses and administration schedules are not reproduced anywhere on this page, because the abstract-level records used to build it do not carry dose figures that can be quoted accurately. Where a number is absent, it is omitted rather than estimated.

1. Module 1 — what Vilon is and how it has been studied
2. Module 2 — mechanism as described in the literature
3. Module 3 — reported outcomes, study by study
4. Module 4 — Vilon side effects: what studies report
5. Module 5 — pharmacokinetics, where data exist
6. Module 6 — regulatory status, stated factually
7. Closing — what the studies did not test

Module 1: What Vilon Is and How It Has Been Studied

Definition and class

Vilon belongs to the group of very short synthetic peptides — two amino acid residues — that Russian gerontology groups developed and described as “peptide bioregulators.” Within that literature it is repeatedly grouped with the tetrapeptide Epithalon (Epitalon, Ala-Glu-Asp-Gly), and several papers tested the two side by side in the same animals, including a DNA-microarray study of mouse heart tissue (PMID 12360356) and studies of the small intestine of aged rats (PMID 12420071). One clinical paper explicitly labels it a “thymomimetic,” that is, a compound the authors positioned as imitating thymic peptide activity (PMID 17152731).

Origin and research context

The compound emerged from a research programme rather than from a pharmaceutical development pipeline that produced a widely registered Western product. Its publication trail clusters in Russian-language journals and in the English translations of Bulletin of Experimental Biology and Medicine, with study types ranging from cell culture to whole-animal experiments. The earliest entries in this verified set date from 2000, including work on cirrhotically altered rat liver (PMID 11033862) and a report on biological age and lifespan indices in mice (PMID 11140587).

Forms encountered in the literature

The indexed studies describe Vilon as a synthetic peptide prepared for experimental administration to animals or for addition to cell and tissue cultures — for example, cultures of human and animal thymus cells, in which researchers compared Vilon with a structural analogue (PMID 23486604). There is no oral consumer dosage form described in this literature set, and the papers do not describe a standardised commercial formulation.

A name collision worth knowing

A literature search for the same letter string returns an unrelated bioinformatics paper: ViLoN, a multi-layer network method for integrating molecular data to stratify patients, published in Nucleic Acids Research (PMID 36395816). That tool has no relationship to the dipeptide; it is an acronym for a computational approach. Readers screening citations should separate the two before drawing conclusions about how much peptide literature exists.

Limits of the evidence

The class label “peptide bioregulator” is a descriptor used by the originating research groups, not a regulatory or pharmacological classification recognised across the wider literature. Much of the record is single-group, single-region work, and several items in the set are Russian-language articles whose full methods are not accessible in English at abstract level. Structural and formulation details are therefore thinly documented compared with what would be expected for a registered drug.

Module 2: Mechanism as Described in the Literature

Gene expression

The most mechanism-oriented item in the verified set is a DNA-microarray experiment in which researchers examined the effects of Vilon and Epithalon on gene expression in mouse heart tissue and reported changes in the expression of a set of genes after peptide administration (PMID 12360356). That paper is the basis for the recurring claim in this literature that very short peptides act at the level of transcriptional regulation rather than as classical receptor agonists.

Immune and thymic activity

A second mechanistic strand is immunological. In cultures of human and animal thymus cells, the study of Vilon and its analogue reported immunomodulating effects on the cultured cells (PMID 23486604). In parallel, an immunohistochemical and morphometric analysis examined how Vilon and Epithalon affected the functional morphology of radiosensitive organs, an approach that looks for cellular and structural correlates of peptide exposure (PMID 11427924).

Tissue-level functional endpoints

Other papers infer mechanism indirectly from organ function. Researchers assessed enzyme activity in the epithelial and subepithelial layers of the small intestine of old rats after Vilon and Epithalon administration (PMID 12660839), and a companion study measured glucose and glycine absorption across different regions of the small intestine in aged rats (PMID 12420071). In the liver, one report examined regeneration and the glycogen-forming function of hepatocytes in rats with cirrhotic changes (PMID 11033862).

Limits of the evidence

No paper in this set identifies a receptor, a binding affinity, or a defined signalling cascade for Vilon. The microarray work describes association between exposure and transcript changes in one tissue of one species, not a validated pathway (PMID 12360356). Functional endpoints such as absorption or enzyme activity are downstream observations that multiple mechanisms could explain. There is no independent replication of the gene-expression findings within this verified set.

Module 3: Reported Outcomes by Study

The table below maps each verified peptide study to its model, its stated endpoints, and what the authors reported. It describes findings only; it is not a summary of benefits, and none of these results establish an outcome in humans outside the specific settings studied.

Limits of the evidence

These are heterogeneous studies with different species, ages, endpoints and durations; they cannot be pooled. Sample sizes, randomisation, blinding and statistical handling are not documented at abstract level for most entries, and the two clinical reports were conducted in patients with diabetes mellitus, so their observations do not transfer to healthy populations (PMID 18306698, PMID 17152731). Lifespan and “biological age” endpoints in rodents are model-specific measures, and the single mouse report does not constitute an anti-ageing finding in any species (PMID 11140587).

Module 4: Vilon Side Effects: What Studies Report

Adverse-event reporting is the weakest part of this literature. None of the verified papers is a dedicated toxicology or safety study, and none of the abstract-level records enumerates a tabulated list of adverse events, withdrawals, or dose-limiting toxicities. What the record contains instead is a set of safety-relevant endpoints measured for other reasons.

• Coagulation and fibrinolysis. Two clinical reports measured haemostatic variables in patients of different ages with diabetes mellitus, one focused on immunity status together with coagulation haemostasis (PMID 18306698) and one on the blood coagulation system and fibrinolysis in type 1 diabetes (PMID 17152731). Because clotting parameters are the kind of measure that can shift in either direction, these papers are the closest the set comes to human safety-relevant monitoring, and the reported changes were framed by the researchers as pharmacodynamic observations rather than as harms.
• Interaction with a cytotoxic drug. One study examined the combined effect of Vilon and cyclophosphane on tumour transplants and on lymphoid tissue explants in mice and rats of various ages, meaning the peptide was evaluated in the presence of chemotherapy and against tumour growth endpoints (PMID 14743610). Co-administration studies of this type are relevant to any discussion of risk, because they test whether a peptide alters the behaviour of transplanted tumours or of lymphoid tissue.
• Organ morphology. An immunohistochemical and morphometric analysis of radiosensitive organs assessed structural change after Vilon and Epithalon, an endpoint that can capture tissue-level injury as well as adaptation (PMID 11427924).
• Immune modulation as a two-sided endpoint. The thymus cell-culture study reported immunomodulating activity in vitro, and immunomodulation is by definition an effect on host defence rather than a purely additive one (PMID 23486604).

Limits of the evidence

Absence of reported adverse events in these papers is not evidence of safety. The studies were not designed or powered to detect harm, no long-term human follow-up appears in the set, and there is no published work here on pregnancy, paediatric exposure, hepatic or renal impairment, immunogenicity, injection-site reactions, or drug interactions beyond the single cyclophosphamide experiment (PMID 14743610). The two clinical papers describe patients already under medical care for diabetes mellitus (PMID 18306698).

Module 5: Pharmacokinetics Where Data Exist

For Vilon, the honest summary is that the verified literature set contains no pharmacokinetic data. None of these papers reports plasma concentrations, half-life, bioavailability, volume of distribution, clearance, metabolite identification, or tissue distribution. The studies are pharmacodynamic and morphological: they measure what changed in an organ, a culture, or a laboratory value, not what the compound concentration was over time.

The closest proxies for distribution are indirect. The mouse heart microarray experiment implies that systemic administration produced measurable transcript changes in cardiac tissue (PMID 12360356), and the intestinal studies imply exposure sufficient to alter enzyme activity and nutrient absorption in gut tissue of aged rats (PMID 12660839, PMID 12420071). Those are inferences about biological effect, not measurements of absorption or elimination.

Limits of the evidence

Without measured pharmacokinetics, no route comparison, no dose-proportionality statement and no interspecies scaling is possible from this literature. Readers should treat any confident claim about how long Vilon “lasts” or how much reaches a given tissue as unsupported by the papers cited on this page.

Module 6: Regulatory Status

Stated factually, and as background rather than legal advice: Vilon is not an approved drug product in the United States. The U.S. Food and Drug Administration has not approved any Vilon-containing medicine, and it does not appear as an approved active ingredient in a marketed U.S. prescription product. It is likewise not a dietary-supplement ingredient with an established lawful marketing history, because peptides of this kind generally fall outside the dietary-ingredient categories.

Material offered under this name in the chemical marketplace is typically labelled research use only (RUO), meaning it is represented as intended for laboratory investigation and not for administration to humans or animals. RUO labelling is a statement about intended use; it does not indicate that a substance has been evaluated for human safety or purity to pharmaceutical standards.

On compounding: under U.S. law, a bulk drug substance used by a 503A compounding pharmacy generally must be the subject of an applicable USP or NF monograph, be a component of an FDA-approved drug, or appear on FDA's list of bulk drug substances that may be used in compounding. Peptides without an approved reference product or monograph do not satisfy those conditions, and FDA has publicly evaluated a number of peptide substances nominated for compounding use. Outside the United States, the historical literature on Vilon is Russian in origin, and the status of any product in a given country depends on that country's own framework (PMID 17152731).

This section describes regulatory concepts for educational purposes and is not legal advice.

Limits of the evidence

Regulatory classifications change, differ by jurisdiction, and are independent of the scientific record. The existence of published animal and small clinical studies does not imply approval, and the absence of approval does not by itself characterise a compound's risk profile.

What the Studies Did Not Test

The verified literature on Vilon leaves large gaps. Specifically, these papers did not test:

• Healthy human populations. The clinical reports in this set enrolled patients of different ages with diabetes mellitus, not healthy volunteers (PMID 18306698, PMID 17152731).
• Human longevity or biological ageing. Lifespan and biological-age endpoints appear only in mice (PMID 11140587).
• Pharmacokinetics and dose-response. No ADME parameters were measured anywhere in the set.
• Long-term safety. No extended human follow-up, no dedicated toxicology study, and no systematic adverse-event collection appears in these reports.
• Replication across independent laboratories. Key mechanistic findings, including the cardiac gene-expression work, stand largely alone within this set (PMID 12360356).
• Cancer outcomes as a therapeutic claim. The tumour-transplant experiment studied combined exposure with cyclophosphane in rodents and explants, not treatment of human cancer (PMID 14743610).
• Modern reporting standards. Most entries predate current trial-registration and reporting conventions, and several are available in English only as abstracts.

Read as a whole, the Vilon literature is an early-stage, geographically concentrated body of work describing biological activity in animals and cell cultures with a small clinical footprint in one patient population. That is a useful starting point for scientific curiosity and an insufficient basis for conclusions about human use. This page remains educational only and is not medical advice; questions about health should go to a licensed physician.

References

• Effect of vilon on biological age and lifespan in mice (Bulletin of Experimental Biology and Medicine, 2000)
• Effect of "vilon" on cirrhotically changed rat liver. Liver regeneration, and status of glycogen-forming function of hepatocytes (Tsitologiia, 2000)
• Immunohistochemical and morphometric analysis of effects of vilon and epithalon on functional morphology of radiosensitive organs (Bulletin of Experimental Biology and Medicine, 2001)
• Studies of the effects of Vilon and Epithalon on gene expression in mouse heart using DNA-microarray technology (Bulletin of Experimental Biology and Medicine, 2002)
• Effect of Vilon and Epithalon on glucose and glycine absorption in various regions of small intestine in aged rats (Bulletin of Experimental Biology and Medicine, 2002)
• Effect of vilon and epithalon on activity of enzymes in epithelial and subepithelial layers in small intestine of old rats (Bulletin of Experimental Biology and Medicine, 2002)
• Effect of dipeptide vilon on emotional stress resistance in rats (Rossiiskii Fiziologicheskii Zhurnal imeni I.M. Sechenova, 2002)
• Combined effect of vilon and cyclophosphane on tumor transplants and lymphoid tissue explants in mice and rats of various age (Advances in Gerontology, 2003)
• Effect of thymomimetic vilon on blood coagulation system and fibrinolisis in diabetes mellitus type 1 patients of different age (Advances in Gerontology, 2006)
• Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus (Advances in Gerontology, 2007)
• Immunomodulating effects of Vilon and its analogue in the culture of human and animal thymus cells (Bulletin of Experimental Biology and Medicine, 2013)
• ViLoN-a multi-layer network approach to data integration demonstrated for patient stratification (Nucleic Acids Research, 2023)